The year 2023 has come to an end. This year, Tsingke adhered to the mission of "Biotech for a better world", insisted on the innovation of science and technology, and committed to the construction of the TSINGKE GENE FACTORY. Let's witness the important moments that will light up 2023!

Adhere to independent innovation, quality first

 As the initiator and practitioner of the concept of "gene factory", Tsingke has always adhered to the concept of digital-enabled technological innovation, and has made key technological breakthroughs in all aspects of the gene factory to realise the automated and intelligent production of gene synthesis, and to promote the development of scientific research, technological innovation, and the application of biotechnology.

In April 2023 Successfully held the “Signing Ceremony of the Nucleic Acid Drug Development Forum and Tsingke Synthetic Biology Jintan Industrial Base Project", and at the same time released the "TsiKer™" high-loading synthesizer, which has become a driving force to promote the construction of the "TSINGKE GENE FACTORY", and boost the high-quality development in the field of nucleic acid drugs.



In August 2023 Completed digital deployment of gene factory and fully online intelligent management system. Gene synthesis has reached stable and fast delivery, with short fragment synthesis as fast as 72 h delivery.


In September 2023, the high-throughput nucleic acid extractor was launched to increase the automated production capacity of the gene factory, achieving a milestone innovation.


Customer first, regional service capacity upgraded

Sequencing laboratory of Fuzhou Branch officially put into use

Fast NGS sequencing lab in Guangzhou Branch was officially put into operation

Tsingke intelligent management system is fully online, gene synthesis has reached stable and fast delivery, short fragment synthesis as fast as 72 h delivery.

Empower customers, win-win co-operation

Participated in 16 exhibitions to provide customers with more efficient and intelligent solutions

Received the research of industry, academia and research from various parties and continue to explore and innovate

Adherence to science and technology, recognised by the industry

Tsingke adheres to the core technology R&D and innovation, and has become the first biopharmaceutical enterprise in China to successfully develop and industrialise long fragment gene synthesis. Our ability of resource integration, scientific and technological innovation, and comprehensive strength of the enterprise have been highly recognised by the industry.


Riding on the momentum of the new start, and forge ahead into the future

Tsingke Biotechnology Co., Ltd. was officially renamed as Beijing Tsingke Biotech Co., Ltd. on 23rd March, 2023, which is the first time for the company to be established in China.

In 2024, Tsingke is committed to partnering with you as we stride towards the future. With the vision of "The Great Tsingke Gene Factory," we will drive progress in the biosynthesis field, fostering high-quality development through our own achievements.